CD20 Antibodies - Biotech, Pharma and Life Science Channel
The chimeric anti-CD20 antibody rituximab (Rituxan & MabThera) from Biogen Idec and Genentech/Roche is one of the world’s commercially most successful antibodies (2007 sales of over US$ 5 bln). Rituximab was first approved in 1997 by the FDA for treatment of B-cell malignancies and in 2006 for 3rd line therapy of rheumatoid arthritis. Genentech, Roche and Biogen Idec have stepwise expanded the indication label of rituximab and are still clinically evaluating new autoimmune indications such as lupus nephritis, multiple sclerosis and vasculitis.
The commercial attractiveness of rituximab has stimulated many companies to create and develop next generation anti-CD20 monoclonal antibodies (mabs) with improved properties compared with the chimeric antibody rituximab. At present, at least nine different anti-CD20 antibodies are in clinical development by competitors of rituximab and by Genentech & Roche themselves (to defend the rituximab market). At least further seven molecules are in preclinical development or pre-IND stage.
Improved anti-CD20 antibodies aim at reducing immunogenicity and the related side effects (infusion and anaphylactic reactions) by fully human or humanized antibodies. Other approaches target at increasing efficacy by binding to different epitopes on the B cell or increasing binding of the mab to the receptor or lowering the off-rate of the mab which results in prolonged presence on the B cell. Furthermore, effector functions are tried to be increased via antigen-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) or increased recruitment of T cells and accessory cells.
Development of subcutaneous instead of the currently used intravenous formulations of the mab may increase convenience of antibody administration. Other engineered anti-CD20 antibodies have reduced CDC to avoid infusion reactions, or are of small size to allow better tissue penetration. One of the next generation anti-CD20 molecules is being developed as a genotype-stratified, tailored therapy, thereby improving outcomes of the therapy by this personalized medicine approach.
News Articles
The Start-up Company Will Develop Therapeutic Antibodies against Novel Targets in the Fields of Cancer and Inflammation Regulatory News: Transgene SA (Euronext...
FARMINGTON, Conn., May 17, 2013 /PRNewswire-iReach/ -- The escalation of new biological drugs, including antibodies and recombinant proteins, is placing renewed emphasis on alternate delivery te...
NEW YORK, May 16, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of adva...
AnaptysBio Awarded U.S. Government Contract To Develop Anti-Ricin Antibodies
SAN DIEGO, May 16, 2013 /PRNewswire/ -- AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the receipt of a contract award from the U.S. government for the developme...
LA JOLLA, Calif. and SHANGHAI, May 16, 2013 /PRNewswire/ -- RuiYi Inc. announced today that it has entered into an exclusive license and collaborative development agreement with Genor BioPharma for th...
MONTREAL, QUEBEC -- (Marketwired) -- 05/16/13 -- Alethia Biotherapeutics Inc., a privately held biotechnology company focusing on the development of therapeutic monoclonal antibodies, announced toda...
Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO
-- First Phase III Data on Obinutuzumab (GA101) in one of the Most Commonly Diagnosed Blood Cancers -- -- Early Stage Data on Investigational Anti-PDL1 Immunotherapy --...
TUSTIN, CA -- (Marketwired) -- 05/14/13 -- Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc., today announced that its recent success in qualifying an antibody-depe...
MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin's Lymphoma
MorphoSys AG / MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin's Lymphoma . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for...
MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non- Hodgkin's Lymphoma
MARTINSRIED / MUNCHEN, GERMANY -- (Marketwired) -- 05/13/13 -- MorphoSys AG / MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non- Hodgkin's Lymphoma . Processed and transmitted by...
Events
6TH ANNUAL RECOMBINANT ANTIBODIES Conference
An insight into novel therapeutics and future technologies
Companies
Source BioScience LifeSciences
Source BioScience LifeSciences are European leaders in DNA sequencing, genomic services, bioinformatic analyses and offers a comprehensive portfolio of genomic reagents and antibodies. Source Bio...
OncoMed Pharmaceuticals is a clinical-stage company that discovers and develops novel therapeutics targeting cancer stem cells, the cells believed to be capable of driving tumor growth, recurrence and...
Onconova, based in Newtown, PA and Lawrenceville, NJ, discovers and develops novel patent- protected small molecule therapeutic agents for cancer, radiation protection and hematol...
Itero Biopharmaceuticals, Inc.
Itero Biopharmaceuticals, Inc. is a specialty biopharmaceutical company focused on the development and commercialization of protein therapeutics that offer significant clinical an...
CytomX Therapeutics is an early stage biotechnology company developing Probodiesâ¢, or proteolytically-activated antibodies. Probodies combine the well-established power and s...
Rockland Immunochemicals has supported the biopharma and diagnostic industries for over 40 years with antibodies and antibody based toolsâ¢Â for basic research, assay develo...
Hycult Biotech is a leader in the fields of immunology and cell biology, we develop, produce and market antibodies, antibody based products and more specifically immunoassays for...
Virdante Pharmaceuticals is developing safer and more effective drugs for autoimmune and inflammatory diseases. Our products incorporate a proprietary âSialic Switchâ te...
Ironwood Pharmaceuticals, Inc. & Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a privately held biotechnology company pursuing the discovery and development of disulfide rich peptides (DRPs) as well differentiated alternati...
Arsanis is committed to the development of monoclonal antibody therapeutics against severe infectious diseases that cannot be controlled with currently available medical treatment...
Clinical Trials
The study evaluates the efficacy and tolerability of an intensified induction and consolidation therapy in combination with rituximab in CD20 positive standard risk patients. Thereafter pa...
Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies
Blood and marrow stem cell transplant has improved the outcome for patients with high-risk hematologic malignancies. However, most patients do not have an appropriate HLA (immune type) ma...
Intensified Post Remission Therapy Containing PEG-Asparaginase
This study is for patients with recently diagnosed blood cancer, called acute lymphoblastic leukemia (ALL). The standard treatment for this disease consists of many chemotherapy drugs tha...
The purpose of this study is to assess the seropersistence of TBE antibodies in children and adolescents aged 1 to 15 years at the time of their first vaccination, 24 months and 34 months...
Rituximab in the Treatment of Graves' Disease
Aim: In a phase II pilot study encompassing 20 patients with Graves’ disease to evaluate the effect of rituximab: 1. Biochemically as assessed by markers of disease activity ( fr...
Immunotherapy of Cancer Using Donor Lymphocytes Labelled With in-Vitro Bispecific Antibodies.
Patients with resistant metastatic solid tumors failing all conventional modalities who are eligible for immunotherapy by bispecific antibodies. First step: NST Second step: Patients with...
Human thyroglobulin (Tg) is the most sensitive biochemical marker for recurrence of differentiated cancer (DTC), especially after the complete removal of thyroid tissue through surgery and...
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes. Monoclonal ant...
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma
This study is for patients with newly diagnosed or relapsed multiple myeloma. The main purpose of this study is to see how their disease responds to consolidation treatment (treatment aim...
Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease
This study is a continued evaluation of the immune response to StaphVAX , a Staphylococcus aureus type 5 and 8 capsular polysaccharide conjugate vaccine, in end-stage renal disease patient...
PubMed Articles
An immunochromatographic strip method, developed with the excretory-secretory antigens from muscle larvae (ML) of Trichinella spiralis labeled with colloidal gold, was used for the detection of anti-T...
Intestinal infection with Trichinella spiralis induces distinct, regional immune responses.
The aim of this study was to evaluate differences between the small and large intestines (SI and LI) with regard to colonization and immunity during infection with Trichinella spiralis. In orally infe...
In vivo studies of aquaporins 3 and 10 in human stratum corneum.
Aquaporins (AQPs) constitute one family of transmembrane proteins facilitating transport of water across cell membranes. Due to their specificity, AQPs have a broad spectrum of physiological functions...
Bovine ephemeral fever (BEF) is an economically important vector-borne viral disease of cattle and buffalo. It has been reported from most of the world's tropical and subtropical regions. In the last...
On-chip immunoassay of a cardiac biomarker in serum using a polyester-toner microchip.
An on-chip immunoassay to detect C-reactive protein (CRP) was performed using a polyester-toner (PT) microchip. CRP is a highly conserved plasma protein responding to inflammation and is used for clin...
A new immunoassay to quantify fungal antigens from the indoor mould Aspergillus versicolor.
Aspergillus versicolor is among the most commonly found moulds in moisture-damaged buildings and can be associated with adverse health effects in humans. This paper reports the development, validation...
Background: The aim of this study was to define immune-related triple negative breast cancer (TNBC) using immunohistochemistry for STAT1, CD20, CD3, IL-8, and IFN-γ and to assess its clinicopathologi...
PURPOSE: Sensitization to HLA antigens resulting in anti-HLA antibodies (panel reactive antibodies; PRA) is a major problem in chronic kidney disease (CKD) patients awaiting transplantation. Induction...
Background The place of monoclonal antibodies in metastatic colorectal cancer has not been clearly defined. Objective To determine the treatment pattern of monoclonal antibodies in colorectal cancer p...
The Immunogenicity of Polyethylene Glycol: Facts and Fiction.
An increasing number of pegylated therapeutic proteins and drug targeting compounds are being introduced in the clinic. Pegylation is intended to increase circulation time and to reduce an immunogenic...
Videos
ESH ITP 2010 "Anti-CD20 monoclonal antibodies .old and new" by Pr. Marc Michel
Introduction of the presentation entitled "Anti-CD20 monoclonal antibodies .old and new" given by Pr. Marc Michel during the ESH (European School of Haematol...
Medical and Biotech [MESH] Definitions
Hepatitis A Antibodies
Antibodies to the HEPATITIS A ANTIGENS including antibodies to envelope, core, and non-structural proteins.
Lectins
Proteins that share the common characteristic of binding to carbohydrates. Some ANTIBODIES and carbohydrate-metabolizing proteins (ENZYMES) also bind to carbohydrates, however they are not considered lectins. PLANT LECTINS are carbohydrate-binding proteins that have been primarily identified by their hemagglutinating activity (HEMAGGLUTININS). However, a variety of lectins occur in animal species where they serve diverse array of functions through specific carbohydrate recognition.
Oligoclonal Bands
Multiple protein bands serving as markers of specific ANTIBODIES and detected by ELECTROPHORESIS of CEREBROSPINAL FLUID or serum. The bands are most often seen during inflammatory or immune processes and are found in most patients with MULTIPLE SCLEROSIS.
Antibodies, Phospho-specific
Antibodies directed against immunogen-coupled phosphorylated PEPTIDES corresponding to amino acids surrounding the PHOSPHORYLATION site. They are used to study proteins involved in SIGNAL TRANSDUCTION pathways. (From Methods Mol Biol 2000; 99:177-89)
Plantibodies
Recombinant antibodies produced in TRANSGENIC PLANTS. The plants serve as BIOREACTORS to produce the antibodies for medical use or industrial processes.
